ImmunisLogoWImmunisLogocropped-immunislogo.pngcropped-immunislogo.png
  • Home
  • About Us
    • Technology
    • Leadership
  • Pipeline
    • Muscle Atrophy
    • Muscle Function
  • Clinical Trials
  • News
    • Awards
    • Features
    • Press Releases
  • Contact
✕
  • Home
  • May 2022 FDA awards Phase 1/2a clinical trial to study the effects of Immunis’ platform immunomodulatory product STEM on muscular atrophy in patients with knee osteoarthritis
Immunis Closes $10 Million Financing Round
May 1, 2022

###

Share

Recent News

  • Sep 10, 2024

    FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial

  • Jul 25, 2024

    Immunis Partners with Springbok Analytics to Assess Clinical Efficacy of IMMUNA in Reversing Sarcopenia

  • Jun 28, 2024

    Immunis Appoints Dr. Christina Weng to its Advisory Board

Navigation

  • Home
  • About Us
    • Technology
    • Leadership
  • Pipeline
    • Muscle Atrophy
    • Muscle Function
  • Clinical Trials
  • News
    • Awards
    • Features
    • Press Releases
  • Contact
  • News

Contact info

Immunis, Inc.
Irvine, California

contact@immunisbiomedical.com

© 2023 Immunis, Inc. | All Rights Reserved